Joshi J Alumkal,Leigh Ellis
Joshi J Alumkal
In March 2026, Ipsen voluntarily withdrew the EZH2 inhibitor tazemetostat (Tazverik) from all markets and indications following results from the confirmatory Phase Ib/III SYMPHONY-1 trial demonstrating hematologic second primary malignancie...
The pan-tumor landscape, allelic status, and genomic complexity of SMARCA4 alterations [0.03%]
泛肿瘤的景观、等位基因状态和SMARCA4改变的基因组复杂性
Matteo Repetto,Michael V Gormally,Jason Chang et al.
Matteo Repetto et al.
Purpose: The clinical implications of distinct SMARCA4 alteration classes remain incompletely defined. We performed a pan-cancer analysis to characterize SMARCA4 mutation classes and their associations with allelic status...
Clinical, genomic, and spatial transcriptomic features of pancreatic adenosquamous carcinoma support subtype-specific therapeutic strategies [0.03%]
胰腺腺鳞癌的临床、基因组和空间转录组特征支持制定亚型特异性治疗策略
S Daniel Haldar,Meredith Wetzel,Jiayun Lu et al.
S Daniel Haldar et al.
Purpose: Pancreatic adenosquamous carcinoma (ASQ) is a rare variant with poorly defined clinical and molecular features compared to conventional pancreatic ductal adenocarcinoma (PDAC). This study aimed to characterize th...
Dual Inhibition of LAG-3 and PD-1 with IBI110 and Sintilimab in Advanced Alveolar Soft Part Sarcoma: A Single-Center, Phase II Trial [0.03%]
LAG-3和PD-1双靶向抑制剂IBI110与Sintilimab治疗晚期肺嗜酸细胞肿瘤的II期临床试验
Zhichao Tan,Jiayin Ruan,Yan Wu et al.
Zhichao Tan et al.
Background: Alveolar soft part sarcoma (ASPS) is an ultra‑rare soft tissue sarcoma. Current standard therapy with PD‑1/PD‑L1 inhibitors achieves limited response rates (
SPEN inactivation drives resistance to androgen receptor pathway inhibitors in metastatic prostate cancer [0.03%]
SPEN失活驱动转移性前列腺癌中雄激素受体通路抑制剂耐药性产生
Steven Blinka,Sonali Arora,Dmytro Rudoy et al.
Steven Blinka et al.
Purpose: Treatment intensification with androgen receptor pathway inhibitors (ARPIs) has become the standard of care for patients with metastatic prostate cancer. However, there remains an unmet need to identify biomarker...
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study [0.03%]
关于用于治疗转移性非小细胞肺癌的血管生成抑制剂雷莫卢单抗:一项针对人的首次一期/二期临床研究
Kristoffer S Rohrberg,Mariana Brandão,Eduardo Castañón Álvarez et al.
Kristoffer S Rohrberg et al.
Purpose: Rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, was evaluated in this first-in-human, multicenter, phase I/II, open-label study (NCT04995523) in checkpoint inhibitor (CPI)-experienced patients with program...
DNMT3B plays antagonistic roles with SMARCB1 and is a targetable vulnerability in rhabdoid tumors [0.03%]
DNMT3B与SMARCB1作用相反并可作为肾母细胞瘤的治疗靶点
Céline Chauvin,Ryszard Wimmer,Ludovica Brunetti et al.
Céline Chauvin et al.
Purpose: Rhabdoid tumors (RTs) are highly aggressive pediatric cancers driven by the biallelic inactivation of the SMARCB1 tumor suppressor gene, the sole recurrent genetic alteration. SMARCB1 encodes a core subunit of th...
Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer [0.03%]
肿瘤浸润B细胞的空間組織可提供免疫檢查點抑制劑在Claudin 18.2表達胃癌中的反應信息
Joseph J Zhao,Choong-Kun Lee,Allison S Y Chan et al.
Joseph J Zhao et al.
Purpose: Claudin 18.2 (CLDN18.2), a tight junction protein normally expressed in gastric epithelium and rendered accessible during malignant transformation, has emerged as a key therapeutic target. Here, we seek to charac...
FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal [0.03%]
美国食品药品监督管理局批准说明书概要:复发或转移性肛管鳞状细胞癌患者的成人患者的复发或转移性肛管鳞状细胞癌的治疗
Shruti U Gandhy,Sandra J Casak,May Tun Saung et al.
Shruti U Gandhy et al.
On May 15, 2025, the Food and Drug Administration approved retifanlimab in combination with carboplatin and paclitaxel for treating unresectable or metastatic squamous cell carcinoma of the anal canal (SCAC), and as a single agent for secon...
Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight loss (A-NEW) Study [0.03%]
乳腺癌幸存者用药减肥的反应:来自适应营养和运动减肥(A-NEW)研究的结果
Jennifer Y Sheng,Marianna L Zahurak,Faith Too et al.
Jennifer Y Sheng et al.
Purpose: Behavioral weight loss interventions (BWL) consisting of remote coaching and self-monitoring have limited effectiveness in breast cancer (BC) survivors. We conducted a single-arm phase II study evaluating additio...